Quick Answer
Petros Pharmaceuticals, Inc. reported Stockholders Equity of -$7.47 million for the year ending 2024.
- Petros Pharmaceuticals, Inc. showed a decrease of -161.9% in Stockholders Equity from 2023 to 2024.
- This data is from Petros Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $1.94 million | Q2 2020: -$3.83 million | Q3 2020: -$7.13 million | Q1 2021: $20.92 million | Q2 2021: $19.49 million | Q3 2021: $17.85 million | Q1 2022: $35.73 million | Q2 2022: $34.22 million | Q3 2022: $20.69 million | Q1 2023: $15.45 million | Q2 2023: $12.94 million | Q3 2023: $6.93 million | Q4 2023: $12.07 million | Q1 2024: $9.79 million | Q2 2024: $8.07 million | Q3 2024: $3.12 million | Q4 2024: -$7.47 million | Q1 2025: -$9.58 million | Q2 2025: $4.45 million | Q3 2025: $3.37 million.
- Over the full 6 years of available data (2019 to 2024), Petros Pharmaceuticals, Inc.'s Stockholders Equity has declined by 193.1%.
- Historical annual values: Fiscal year 2024: -$7.47 million | Fiscal year 2023: $12.07 million | Fiscal year 2022: $16.70 million | Fiscal year 2021: $35.54 million | Fiscal year 2020: $17.47 million | Fiscal year 2019: $8.02 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: